Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Spencer Pharmaceutical Inc. (SPPH)
Boston, US
Spencer Pharmaceutical Inc. is dedicated to pioneering drug delivery platforms aimed at addressing neurological conditions. A core aspect of their expertise lies in the precise, controlled administration of existing therapeutic compounds for central nervous system disorders, such as Alzheimer's, Parkinson's disease, and various forms of brain cancer. Moreover, the company holds a proprietary slow-release drug delivery system, which is utilized for managing type-2 diabetes and arthritis, and holds promise for other medical applications. Its operations are predominantly located in North America and Europe. Spencer Pharmaceutical Inc. was established in 1998 and maintains its headquarters in Boston, Massachusetts.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +9,900.00% | +9,900.00% | +9,900.00% | +9,900.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-100.0%
-
EPS growth Medical - Pharmaceuticals: +20.2%+66.7% ★ Q1'04: -100.0% (vs Q1'03)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%— Q1'04: -12.3% (vs Q1'03)
-
EBIT margin Medical - Pharmaceuticals: +6.8%— Q1'04: -73.8% (vs Q1'03)
-
ROIC Medical - Pharmaceuticals: +6.1%-21.6% Q1'04: -45.2% (vs Q1'03)
-
Share dilution Medical - Pharmaceuticals: +0.0%+5.0% Q1'04: +73.6% (vs Q1'03)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.18× Q1'04: -0.29× (vs Q1'03)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Maximilien Arella | Chairman, Chief Executive Officer and President | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SPPH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
